These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38513258)

  • 21. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.
    Mastorino L; Susca S; Cariti C; Sliquini N; Verrone A; Stroppiana E; Ortoncelli M; Dapavo P; Ribero S; Quaglino P
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1848-1853. PubMed ID: 37113043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.
    Mostafa NM; Nader AM; Noertersheuser P; Okun M; Awni WM
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):490-497. PubMed ID: 27545848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
    Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
    Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
    Griffiths CEM; Papp KA; Kimball AB; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    J Drugs Dermatol; 2018 Aug; 17(8):826-832. PubMed ID: 30124721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis.
    Andersen CSB; Kvist-Hansen A; Siewertsen M; Enevold C; Hansen PR; Kaur-Knudsen D; Zachariae C; Nielsen CH; Loft N; Skov L
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.
    Reich K; Gordon KB; Strober B; Langley RG; Miller M; Yang YW; Shen YK; You Y; Zhu Y; Foley P; Blauvelt A
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):2393-2400. PubMed ID: 35920762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
    Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
    Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
    Zangrilli A; Bavetta M; Scaramella M; Bianchi L
    G Ital Dermatol Venereol; 2018 Apr; 153(2):146-154. PubMed ID: 29564871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis.
    Loft N; Bregnhøj A; Fage S; Nielsen CH; Enevold C; Zachariae C; Iversen L; Skov L
    Dermatol Ther; 2021 Nov; 34(6):e15106. PubMed ID: 34418225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks.
    Rompoti N; Politou M; Stefanaki I; Vavouli C; Papoutsaki M; Neofotistou A; Rigopoulos D; Stratigos A; Nicolaidou E
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):689-697. PubMed ID: 36562663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
    Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
    Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
    Gordon K; Papp K; Poulin Y; Gu Y; Rozzo S; Sasso EH
    J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Reich K; Gooderham M; Thaçi D; Crowley JJ; Ryan C; Krueger JG; Tsai TF; Flack M; Gu Y; Williams DA; Thompson EHZ; Paul C
    Lancet; 2019 Aug; 394(10198):576-586. PubMed ID: 31280967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
    Pinter A; Puig L; Schäkel K; Reich A; Zaheri S; Costanzo A; Tsai TF; Smith SD; Lynde C; Brnabic A; Reed C; Hill J; Schuster C; Riedl E; Paul C
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2087-2100. PubMed ID: 35766124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of immunogenicity testing for cost-effective management of psoriasis patients treated with adalimumab.
    Mota F; Neves E; Oliveira JC; Selores M; Torres T
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):33-35. PubMed ID: 28632883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.
    Mahil SK; Arkir Z; Richards G; Lewis CM; Barker JN; Smith CH
    Br J Dermatol; 2013 Aug; 169(2):306-13. PubMed ID: 23550925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.
    Feldman SR; Merola JF; Pariser DM; Zhang J; Zhao Y; Mendelsohn AM; Gottlieb AB
    J Dermatolog Treat; 2022 May; 33(3):1670-1675. PubMed ID: 33678106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.